Latest Intelligence on Therapy Area in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: INFORM-1 results highlight the potential of interferon-free HCV therapy

Preliminary results from INFORM-1, the first study to evaluate the combination of two small molecule antivirals in hepatitis C, demonstrated significant reductions of viral load in the disease. Given the impressive findings, Datamonitor believes that interferon-free therapy will become the new standard of care once small molecule antivirals with distinct targets reach the market.

Published By Datamonitor
28 Apr 2009
CommentWire
CommentWire

Roche: implementing cuts to maintain its strong fiscal position

In light of R&D setbacks and slowing sales growth, Roche has outlined a number of cost-saving initiatives, including the termination of 4,800 jobs. Despite a challenging year, Roche's above-average operating profit in 2009 is expected to be maintained, and these new initiatives are expected to result in cost savings of up to $2.4bn per year, leaving the company in a strong financial position.

Published By Datamonitor
17 Nov 2010
Expert View
Expert View

Roche/Genentech/Biogen Idec: Rituxan delays need for new therapy in follicular lymphoma

New data show that immediate treatment with Rituxan provides an impressive reduction in follicular lymphoma progression rates. These results could lead to a change in the management of newly diagnosed asymptomatic follicular lymphoma patients and increased uptake of Rituxan in the seven major markets.

Published By Datamonitor
13 Dec 2010
Expert View
Expert View

Rise of the superbug set to drive antibacterials growth

The increasing incidence of multi-resistant superbugs is emerging as a major global health concern. Although there are several candidates for the treatment of methicillin-resistant Staphylococcus aureus other pathogens such Pseudomonas aeruginosa or Acinetobacter Baumannii pose an even larger threat. This largely unmet urgent need for treatments should drive growth in the antibacterials market.

Published By Datamonitor
09 Mar 2007
ResearchWire
ResearchWire

Rheumatoid arthritis: research points to genetic component

Published By Datamonitor
28 Jun 2007
ResearchWire
ResearchWire

Pulmonary arterial hypertension: market on the pulse of global growth

Published By Datamonitor
17 Mar 2006
ResearchWire
ResearchWire

Psoriasis market: Humira set to overtake Enbrel

Published By Datamonitor
22 Jan 2007
CommentWire
CommentWire

Prostate cancer: new study could clear up vitamin E debate

Published By Datamonitor
30 Jul 2001
Expert View
Expert View

Pipeline antipsychotic drugs will drive the next market evolution

Antipsychotic pipeline developers have been in the spotlight of late following a number of significant regulatory developments, including the FDA's approval of Johnson & Johnson's Invega Sustenna. With a global value of around $22 billion in 2008, and given their status as the leading drug class in the US, the commercial opportunity for novel pipeline antipsychotics is considerable.

Published By Datamonitor
07 Aug 2009
CommentWire
CommentWire

Pfizer: stacking up positive data for new rheumatoid arthritis drug

Positive results from a second Phase III trial take Pfizer's tofacitinib one step closer to becoming the first novel oral small molecule for the treatment of rheumatoid arthritis. While these data contribute to tofacitinib's clinical and commercial offering, pricing and product positioning remains a concern. Nonetheless Datamonitor views tofacitinib as a future blockbuster in rheumatoid arthritis.

Published By Datamonitor
07 Mar 2011

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.